Managed Asset Portfolios LLC Acquires Shares of 8,400 Zoetis Inc. $ZTS

Managed Asset Portfolios LLC bought a new position in shares of Zoetis Inc. (NYSE:ZTS) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 8,400 shares of the company’s stock, valued at approximately $1,229,000.

Other large investors have also recently made changes to their positions in the company. Halbert Hargrove Global Advisors LLC lifted its holdings in Zoetis by 496.6% during the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after buying an additional 144 shares in the last quarter. NewSquare Capital LLC grew its stake in Zoetis by 69.1% in the 2nd quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock worth $32,000 after acquiring an additional 85 shares in the last quarter. Financial Consulate Inc. purchased a new position in shares of Zoetis during the third quarter worth approximately $39,000. SJS Investment Consulting Inc. raised its stake in shares of Zoetis by 1,606.3% during the third quarter. SJS Investment Consulting Inc. now owns 273 shares of the company’s stock valued at $40,000 after acquiring an additional 257 shares in the last quarter. Finally, TruNorth Capital Management LLC purchased a new stake in shares of Zoetis in the third quarter valued at approximately $42,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ZTS has been the topic of several research reports. Piper Sandler restated a “neutral” rating and set a $135.00 price objective (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. Morgan Stanley set a $160.00 price target on Zoetis in a research report on Thursday, December 18th. The Goldman Sachs Group upgraded Zoetis to a “buy” rating in a report on Monday, December 15th. Barclays started coverage on shares of Zoetis in a research note on Monday, December 8th. They issued an “equal weight” rating and a $136.00 price objective for the company. Finally, HSBC set a $140.00 target price on shares of Zoetis in a research report on Wednesday, December 10th. Six research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Zoetis has a consensus rating of “Hold” and an average price target of $152.91.

Zoetis Trading Down 2.3%

Shares of NYSE ZTS opened at $126.01 on Wednesday. Zoetis Inc. has a 1-year low of $115.25 and a 1-year high of $177.00. The business has a fifty day moving average price of $126.21 and a 200 day moving average price of $133.55. The stock has a market capitalization of $53.19 billion, a P/E ratio of 20.93, a price-to-earnings-growth ratio of 1.97 and a beta of 0.95. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.08. The company had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The firm’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Equities research analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be given a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a yield of 1.7%. Zoetis’s dividend payout ratio is presently 35.22%.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.